SRPT — Sarepta Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.88bn
- $1.94bn
- $2.20bn
Brief: Sarepta Therapeutics To Report 3-Year Topline Data From Embark Study Of Elevidys Gene Therapy
Brief: Sarepta Reconfirms Yearly Sales Floor For ELEVIDYS Of $500.0 Mln
Sarepta falls after preliminary Q4 Elevidys revenue misses estimates
Sarepta Therapeutic Q4 prelim net product revenue misses estimates
Brief: Sarepta Therapeutics Announces Submission Of Clinical Trial Application For Srp-1005
Brief: Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Walt Disney, Titan Mining, Costco Wholesale
U.S. STOCKS ON THE MOVE-Nordson, Walt Disney, Titan Mining
U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill
Sarepta dips after announcing debt refinancing
Brief: Sarepta Therapeutics Announces Refinancing Of Approximately $291 Million Of 1.25% Convertible Senior Notes Due 2027
U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Dell
U.S. STOCKS ON THE MOVE-Applied Materials, CDW, Kohl's
Sarepta rises after U.S. FDA clears study of muscle-wasting disease drug
Brief: Sarepta Provides Progress Update For Srp-1003, Its Treatment For Myotonic Dystrophy Type 1
Street View: Sarepta's Elevidys label update in line with expectations
US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries (updated)
US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries
U.S. STOCKS ON THE MOVE-Targa Resources, Illumina, Alphabet